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Available online 24 February 2016AbstractCRISPR/Cas9 system confers molecular immunity in archeal and bacterial species against invading foreign nucleic acids. CRISPR/Cas9
system is used for genome engineering applications across diverse eukaryotic species. In this study, we demonstrate the utility of the CRISPR/
Cas9 genome engineering system for drug target validation in human cells. Pladienolide B is a natural macrolide with antitumor activities
mediated through the inhibition of pre-mRNA splicing. To validate the spliceosomal target of Pladienolide B, we employed the CRSIPR/Cas9
system to introduce targeted mutations in the subunits of the SF3B complex in the HEK293T cells. Our data reveal that targeted mutagenesis of
the SF3b1 subunit exhibited higher levels of resistance to Pladienolide B. Therefore, our data validate the spliceosomal target of Pladienolide B
and provide a proof of concept on using the CRISPR/Cas9 system for drug target identification and validation.
© 2016 The Authors. Published by Elsevier B.V. on behalf of Socie´te´ Franc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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functional analysis studies in basic biology and applied
biotechnology [1,2]. Site-specific nucleases (SSNs) that can be
customized to specifically bind and cleave a user-defined
sequence have been developed including zinc finger nucle-
ases (ZFNs), transcription activator like nucleases (TALENs)
and clustered regularly interspaced short palindromic repeats
(CRISPR)/CRISPR associated (Cas9) systems [3e6]. SSNs
generate double strand breaks (DSBs) that are repaired by
either the error-prone non-homologous end joining (NHEJ) or
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to its facile engineering and higher efficiencies, CRISPR/Cas9
system is the platform of choice for targeted editing and
mutagenesis of eukaryotic genomes [9,10]. Therefore,
CRISPR/Cas9 has been used across diverse eukaryotic species
for targeted genome editing and regulation and for functional
analysis studies [3e5].
Studies of drug target discoveries were hindered by the lack
of efficient and reproducible-targeted modification of
mammalian genomes. The efficiency of the CRISPR/Cas9
system, and the ability of modifying several targets simulta-
neously (multiplexing), and amenability of sgRNA library
construction and screening are poised to expedite the drug
discovery and development efforts for different applications
including the treatment of human diseases [5,11e15]. Pla-
dienolide B (PB), a natural product with antitumor activities
isolated from Streptomyces platensis and shown to bind the
SAP130 subunit of the SF3B complex [16,17]. The SF3B
complex is part of the U2 snRNP complex [18e20]. Binding
of PB to the SF3B complex blocks splicing and promptsnc¸aise de Biochimie et Biologie Mole´culaire (SFBBM). This is an open access
c-nd/4.0/).
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Here, we attempted to validate the molecular target of the PB
in the SF3B complex. Therefore, we generated sgRNAs with
binding specificities to all SF3B subunits. We performed
transfections into HEK293T cells using Cas9 endonuclease
driven by the b-chicken promoter and sgRNA driven by the
U6 promoter (Fig. S1A). We designed several sgRNAs to
target some subunits of the spliceosome complex that is
including some of SF3B complex such as SF3B1, SF3B2,
SF3B3 [23] and SF3A complex such as SF3A3 (Fig. S1B and
Supporting information and Table S2). Catalytically inactive
Cas9 (dCas9) was used as a negative control (Fig. S1A). Three
days post-transfection, cells were collected and genomic DNA
purified and subjected to T7 Endonuclease I (T7EI) mutation
detection assays. Our data reveal high levels of targeted
mutagenesis of the SF3B subunits as demonstrated by T7EI
mutation detection assays (Fig. 1AeD). To validate the tar-
geted mutagenesis efficiencies and precisely determine the
nature of indels, we PCR-amplified fragments encompassing
the target sites, SF3B1, SF3B2, SF3B3, and SF3A3, and cloned
the amplicons. Subsequently, we subjected these clones to
Sanger sequencing and analyzed the presence of indels and the
efficiency of targeted mutagenesis (Fig. 1AeD). We achieved
23% of targeted mutagenesis of the SF3B1 subunit, 37.5% for
the SF3B2, 35.7% for the SF3B3 subunit and 20% for the
SF3A3 subunit (Fig. 1E).
Having achieved higher levels of targeted mutagenesis in
all subunits of the SF3B complex, we proceeded to investigateFig. 1. Detection of the targeted modification of each spliceosome subunit by T7E
sequencing reads of PCR amplicons encompassing the targets of SF3b1, SF3b2, SF
PAM sequence is underlined, dashes indicate nucleotide deletions, nucleotides highl
substitutions. Arrow indicates the expected size of the DNA bands of correspondin
estimated by the number of mutant clones divided by the total number of sequencthe effects of the targeted mutagenesis of each subunit to the
sensitivity to PB. Three days post transfection, cells were
collected and seeded again in a 24 well culture plate and
cultured for 24 h prior treatment with increasing concentra-
tions of PB (1e100 nM) and incubated for 24 h at 37 C
humidified incubator with 5% CO2. Subsequently, at the end
of incubation time the media was removed and we performed
cell viability assays using Almar Blue (AB) [24e26]. Using
this assay, it is possible to spectrophotometrically measure the
cellular proliferation. Resazurin (oxidized form) is blue and
non-fluorescent, whereas resorufin (reduced form) is red and
highly fluorescent. Therefore, AB reduction is a suitable in-
dicator of the cellular viability [27]. The AB assays were
carried out according to manufacturer's instructions. In each
experiment, wells containing only the AB solution without
cells were also prepared and incubated for 5 h (Fig. 2).
HEK293T cells edited in SF3B1 subunit of the spliceosome
complex and treated with 100 nM concentration of PB showed
a red color when compared to the cells un-transfected or
transfected with only sgRNA or wtCas9 only indicating more
resorufin accumulation and high level of resistance to the PB
(Fig. 2). Higher cell viability levels (50% ± 8) were detected
in population of cells co-transfected with wtCas9 and a
sgRNA targeting SF3B1 compared to lower cell viability
levels (23% ± 5) for cells co-transfected with dCas9 and
sgRNA targeting SF3B1 (Fig. 2). However, no significant
difference has been observed in HEK293T cells co-transfected
with SF3B2, SF3B3 or SF3A3 indicating that SF3b1 is theI assay and Sanger sequencing. (AeD) T7EI assays and alignment of Sanger
3b3 and SF3a3 genes respectively. SgRNAs targets are highlighted in red, the
ighted in blue indicate insertions, and nucleotides highlighted in green indicate
g amplicons cleaved by T7EI. (E) Genome editing efficiency in each subunit
ed clones.
Fig. 2. Effect of the specific gene editing on the toxicity of the antitumor
macrolide Pladienolide B on the HEK293T cells. (A) Cell viability was
assessed by colorimetric assay using Alamar Blue Cell Viability Reagent (Life
Technologies, UK). HEK293T cells edited in various genes (SF3A3, SF3B1,
SF3B2, and SF3B3) and treated with 100 nM of Pladienolide B for 24 h at
37 C humidified incubator with 5% CO2. Specific deletion of SF3B1 dis-
played high level of resistance to the PB when compared to the un-transfected
cells or cells transfected only with wtCas9, or sgRNA or dCas9. Result is a
representative of three independent experiments and the bars represents the
mean ± SD and *P < 0.01.
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conclusions of previous work from Yokoi et al., where a
mutation in the gene for SF3B1 was shown to confer resistance
to the inhibitory action of PB [17]. Therefore, CRISPR/Cas9
system could be used to identify a target of known drugs by
using a specific subset of sgRNAs and screening their potential
targets. Furthermore, sgRNA libraries with genome-wide tar-
gets could be employed to generate functional knock outs for
the purpose of identifying drug targets (Fig. S2). Our data
validate that the SF3B1 is the bona fide molecular target the
PB and indicate the power of this technology in identifying
existing and novel drug targets. Such applications would
revolutionize the drug discovery and development efforts, and
lead to the next generation of smart and personalized drugs.
Our study extends the utility of the CRISPR/Cas9 system
for drug discovery and development applications. Molecular
target validation of PB would unlock the possibilities of
developing new synthetic analogues that are cheaper and more
stable with superb antitumor activities. Furthermore, target
knockouts of genes of key cellular machineries, could be used
to discover novel drugs from synthetic and natural chemical
libraries. Different platforms for genome-wide interrogation of
gene function have been recently developed [28]. Such plat-
forms could be utilized to identify the molecular targets of
existing drugs, and for novel drug discovery (Fig. S2).
Furthermore, such a platform would be helpful in identifying
interacting genes and pathways with the primary drug target.
By manipulating those interacting genes and pathways, we
could increase the efficacy of the current drugs and develop
much more powerful drugs. In conclusion, CRISPR/Cas9system serves as a key tool in the molecular toolbox for drug
discovery and development.
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